246 related articles for article (PubMed ID: 34238254)
21. Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics.
Zhang X; Belkina N; Jacob HK; Maity T; Biswas R; Venugopalan A; Shaw PG; Kim MS; Chaerkady R; Pandey A; Guha U
Proteomics; 2015 Jan; 15(2-3):340-55. PubMed ID: 25404012
[TBL] [Abstract][Full Text] [Related]
22. Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors.
Casado P; Alcolea MP; Iorio F; Rodríguez-Prados JC; Vanhaesebroeck B; Saez-Rodriguez J; Joel S; Cutillas PR
Genome Biol; 2013 Apr; 14(4):R37. PubMed ID: 23628362
[TBL] [Abstract][Full Text] [Related]
23. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
Zimmerman EI; Turner DC; Buaboonnam J; Hu S; Orwick S; Roberts MS; Janke LJ; Ramachandran A; Stewart CF; Inaba H; Baker SD
Blood; 2013 Nov; 122(22):3607-15. PubMed ID: 24046014
[TBL] [Abstract][Full Text] [Related]
24. RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation.
Schwäble J; Choudhary C; Thiede C; Tickenbrock L; Sargin B; Steur C; Rehage M; Rudat A; Brandts C; Berdel WE; Müller-Tidow C; Serve H
Blood; 2005 Mar; 105(5):2107-14. PubMed ID: 15536149
[TBL] [Abstract][Full Text] [Related]
25. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.
Grundy M; Seedhouse C; Shang S; Richardson J; Russell N; Pallis M
Mol Cancer Ther; 2010 Mar; 9(3):661-72. PubMed ID: 20159992
[TBL] [Abstract][Full Text] [Related]
26. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.
Zauli G; Celeghini C; Melloni E; Voltan R; Ongari M; Tiribelli M; di Iasio MG; Lanza F; Secchiero P
Haematologica; 2012 Nov; 97(11):1722-30. PubMed ID: 22689683
[TBL] [Abstract][Full Text] [Related]
27. Phosphoproteomics-Based Profiling of Kinase Activities in Cancer Cells.
Wirbel J; Cutillas P; Saez-Rodriguez J
Methods Mol Biol; 2018; 1711():103-132. PubMed ID: 29344887
[TBL] [Abstract][Full Text] [Related]
28. Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms.
Ruvolo PP; Ma H; Ruvolo VR; Zhang X; Mu H; Schober W; Hernandez I; Gallardo M; Khoury JD; Cortes J; Andreeff M; Post SM
Haematologica; 2017 Dec; 102(12):2048-2057. PubMed ID: 28912176
[TBL] [Abstract][Full Text] [Related]
29. ATRA can enhance apoptosis that is induced by Flt3 tyrosine kinase inhibition in Flt3-ITD positive cells.
Scholl S; Müller R; Clement JH; Loncarevic IF; Böhmer FD; Höffken K
Leuk Res; 2006 May; 30(5):633-42. PubMed ID: 16473406
[TBL] [Abstract][Full Text] [Related]
30. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
Garcia JS; Percival ME
Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
[TBL] [Abstract][Full Text] [Related]
31. Large-scale proteomics analysis of the human kinome.
Oppermann FS; Gnad F; Olsen JV; Hornberger R; Greff Z; Kéri G; Mann M; Daub H
Mol Cell Proteomics; 2009 Jul; 8(7):1751-64. PubMed ID: 19369195
[TBL] [Abstract][Full Text] [Related]
32. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
33. Natural and Semisynthetic Chalcones as Dual FLT3 and Microtubule Polymerization Inhibitors.
Malik HS; Bilal A; Ullah R; Iqbal M; Khan S; Ahmed I; Krohn K; Saleem RSZ; Hussain H; Faisal A
J Nat Prod; 2020 Oct; 83(10):3111-3121. PubMed ID: 32975953
[TBL] [Abstract][Full Text] [Related]
34. A tyrosine kinase-STAT5-miR21-PDCD4 regulatory axis in chronic and acute myeloid leukemia cells.
Espadinha AS; Prouzet-Mauléon V; Claverol S; Lagarde V; Bonneu M; Mahon FX; Cardinaud B
Oncotarget; 2017 Sep; 8(44):76174-76188. PubMed ID: 29100302
[TBL] [Abstract][Full Text] [Related]
35. A potential therapeutic target for FLT3-ITD AML: PIM1 kinase.
Fathi AT; Arowojolu O; Swinnen I; Sato T; Rajkhowa T; Small D; Marmsater F; Robinson JE; Gross SD; Martinson M; Allen S; Kallan NC; Levis M
Leuk Res; 2012 Feb; 36(2):224-31. PubMed ID: 21802138
[TBL] [Abstract][Full Text] [Related]
36. Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.
Li X; Wang A; Yu K; Qi Z; Chen C; Wang W; Hu C; Wu H; Wu J; Zhao Z; Liu J; Zou F; Wang L; Wang B; Wang W; Zhang S; Liu J; Liu Q
J Med Chem; 2015 Dec; 58(24):9625-38. PubMed ID: 26630553
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive characterization of the phosphoproteome of gastric cancer from endoscopic biopsy specimens.
Abe Y; Hirano H; Shoji H; Tada A; Isoyama J; Kakudo A; Gunji D; Honda K; Boku N; Adachi J; Tomonaga T
Theranostics; 2020; 10(5):2115-2129. PubMed ID: 32089736
[No Abstract] [Full Text] [Related]
38. Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors.
Balabanov S; Wilhelm T; Venz S; Keller G; Scharf C; Pospisil H; Braig M; Barett C; Bokemeyer C; Walther R; Brümmendorf TH; Schuppert A
PLoS One; 2013; 8(1):e53668. PubMed ID: 23326482
[TBL] [Abstract][Full Text] [Related]
39. Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia.
Liang X; Wang B; Chen C; Wang A; Hu C; Zou F; Yu K; Liu Q; Li F; Hu Z; Lu T; Wang J; Wang L; Weisberg EL; Li L; Xia R; Wang W; Ren T; Ge J; Liu J; Liu Q
J Med Chem; 2019 Jan; 62(2):875-892. PubMed ID: 30565931
[TBL] [Abstract][Full Text] [Related]
40. Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies.
Oveland E; Fladmark KE; Wergeland L; Gjertsen BT; Hovland R
Curr Pharm Biotechnol; 2006 Jun; 7(3):185-98. PubMed ID: 16789903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
